solifenacin succinate has been researched along with Disease Models, Animal in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kociszewski, J; Poleszak, E; Serefko, A; Szopa, A; Wiśniewski, R; Woźniak, A; Wróbel, A | 1 |
| He, Y; Jiang, J; Shen, C; Wang, W; Yang, B; Yu, Y | 1 |
| He, Y; Liu, Q; Xu, H; Xu, J; Yang, B; Yu, Y | 1 |
| Kadekawa, K; Nishijima, S; Noguchi, K; Sugaya, K; Ueda, T; Yamamoto, H | 1 |
| Imamura, T; Ishizuka, O; Minagawa, T; Nagai, T; Nakazawa, M; Ogawa, T; Saito, T; Suzuki, T; Yokoyama, H | 1 |
| Miyata, K; Ohtake, A; Sasamata, M; Sato, S | 1 |
| Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A | 1 |
| Akino, H; Aoki, Y; Ito, H; Nagase, K; Tanase, K; Yokoyama, O | 1 |
| Colli, E; Digesu, GA; Olivieri, L | 1 |
| Ikeda, K; Kobayashi, S; Miyata, K; Suzuki, M; Yamada, T | 1 |
2 review(s) available for solifenacin succinate and Disease Models, Animal
| Article | Year |
|---|---|
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgen
Topics: Adenosine Triphosphate; Afferent Pathways; Animals; Disease Models, Animal; Humans; Muscarinic Antagonists; Muscle Contraction; Quinuclidines; Rats; Receptors, Muscarinic; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2010 |
Overactive bladder treatments in early phase clinical trials.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drugs, Investigational; Guanidines; Humans; Mice; Muscarinic Antagonists; Quinuclidines; Receptors, Muscarinic; Sensitivity and Specificity; Severity of Illness Index; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Bladder, Overactive | 2007 |
8 other study(ies) available for solifenacin succinate and Disease Models, Animal
| Article | Year |
|---|---|
Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways.
Topics: Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Duloxetine Hydrochloride; Female; Locomotion; Rats; Rats, Wistar; Signal Transduction; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2020 |
Resveratrol improves urinary dysfunction in rats with chronic prostatitis and suppresses the activity of the stem cell factor/c-Kit signaling pathway.
Topics: Animals; Chronic Disease; Diphtheria-Tetanus-Pertussis Vaccine; Disease Models, Animal; Down-Regulation; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostate; Prostatitis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Resveratrol; Signal Transduction; Solifenacin Succinate; Stem Cell Factor; Stilbenes; Urinary Bladder | 2017 |
Combination of Luteolin and Solifenacin Improves Urinary Dysfunction Induced by Diabetic Cystopathy in Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Drug Therapy, Combination; Luteolin; Male; Proto-Oncogene Proteins c-kit; Rats, Wistar; Solifenacin Succinate; Stem Cell Factor; Urinary Bladder | 2018 |
Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury.
Topics: Acetanilides; Animals; Disease Models, Animal; Female; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Spinal Cord Injuries; Thiazoles; Urethra; Urinary Bladder; Urological Agents | 2020 |
Combined treatment with a β
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Cold Temperature; Disease Models, Animal; Drug Therapy, Combination; Female; Muscarinic Antagonists; Rats; Rats, Inbred SHR; Solifenacin Succinate; Stress, Physiological; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urological Agents | 2017 |
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Topics: Adenosine Triphosphate; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Cystitis; Disease Models, Animal; Down-Regulation; Female; Hydrochloric Acid; Mandelic Acids; N-Methylscopolamine; Organophosphonates; Phenols; Phenylpropanolamine; Pirenzepine; Polycyclic Compounds; Pyridoxal Phosphate; Pyrrolidines; Quinuclidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Receptors, Purinergic; Solifenacin Succinate; Tetrahydroisoquinolines; Tolterodine Tartrate; Urinary Bladder; Urination; Urodynamics | 2010 |
Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Female; Infarction, Middle Cerebral Artery; Muscarinic Antagonists; Muscle Contraction; Organ Size; Quinuclidines; Rats; Rats, Sprague-Dawley; Solifenacin Succinate; Statistics, Nonparametric; Sulfonamides; Tamsulosin; Tetrahydroisoquinolines; Urinary Bladder; Urinary Bladder, Overactive | 2011 |
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
Topics: Animals; Bethanechol; Cholera Toxin; Colonic Diseases, Functional; Defecation; Diarrhea; Dinoprostone; Disease Models, Animal; Intestines; Isoquinolines; Male; Muscarinic Antagonists; Neostigmine; Nicotine; Quinuclidines; Rats; Receptor, Muscarinic M3; Receptors, Muscarinic; Serotonin; Solifenacin Succinate; Stress, Physiological; Tetrahydroisoquinolines | 2001 |